(Q41249045)

28 September 2017

1 reference

title

External beam radiation therapy does not offer long-term control of prostate cancer (English)

1 reference

adaptive radiation therapy

28 September 2017

main subject

0 references

author name string

Goluboff ET

series ordinal

1

1 reference

28 September 2017

Benson MC

series ordinal

2

1 reference

28 September 2017

publication date

1 November 1996

1 reference

Urologic Clinics of North America

28 September 2017

published in

1 reference

28 September 2017

volume

23

1 reference

28 September 2017

issue

4

1 reference

28 September 2017

page(s)

617-621

1 reference

Recent results of management of palpable clinically localized prostate cancer

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

5-Year Tumor Recurrence Rates After Anatomical Radical Retropubic Prostatectomy For Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Frequency of residual neoplasm in the prostate following three-dimensional conformal radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Early Prostate Cancer: The National Results of Radiation Treatment from the Patterns of Care and Radiation Therapy Oncology Group Studies With Prospects for Improvement with Conformal Radiation and Adjuvant Androgen Deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Impact of Radical Prostatectomy in the Management of Clinically Localized Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Radical surgery versus radiotherapy for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Cancer statistics, 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Prostate Specific Antigen as an Outcome Variable for T1 and T2 Prostate Cancer Treated by Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Prostate-specific antigen and radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Radical Prostatectomy and Radical Radiation Therapy for Clinical Stages T1 to 2 Adenocarcinoma of the Prostate: New Insights into Outcome from Repeat Biopsy and Prostate Specific Antigen Followup

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970340-2

7 January 2021

10.1016/S0094-0143(05)70340-2

Identifiers

DOI

1 reference

28 September 2017

1 reference